An important event in the treatment of inflammatory disease was the identification of selective inhibitors of cyclooxygenase-2 (COX-2). Cyclooxygenase-1 (COX-1) inhibitors are responsible for many of the adverse effects of nonsteroidal anti-inflammatory drugs, such as gastrointestinal disturbances, while blockage of COX-2 mediates the anti-inflammatory activity with fewer adverse effects. Selective COX-2 inhibitors include rofecoxib (Vioxx; Merck & Co, West Point, Pa), celecoxib (Celebrex; Pfizer Inc, New York, NY), valdecoxib (Bextra; Pfizer Inc), and lumiracoxib (Prexige; Novartis Pharmaceuticals Corp, Basel, Switzerland). Nimesulide (Ainex; Schering-Plough, Santiago, Chile) (and other trade names), and etolodac (Lodine; Wyeth, Madison, NJ) also exhibit selective COX-2 inhibition and can be included in this class of medication which is used in the treatment of osteoarthritis, rheumatoid arthritis, acute pain, and dysmenorrhea.1 Nimesulide and lumiracoxib are not approved by the Food and Drug Administration and are not marketed in the United States and Merck removed Vioxx from the market worldwide in September 2004 because of a possible increased risk of heart attack and stroke.
From the literature, there are 8 case reports of visual disturbance from treatment with COX-2 inhibitors.2- 3 These include orange spots in vision while taking celecoxib, temporary blindness from rofecoxib, a jellybean-like area of vision loss centrally from celecoxib, and 5 cases of blurred vision (4 cases related to celecoxib and 1 related to rofecoxib). The visual disturbances all resolved within 72 hours of discontinuing the drug (positive dechallenge), however no rechallenge data (that the adverse reaction reoccurred when restarting the drug) is available.
Recently, a large number of inquiries and case reports were submitted to the National Registry of Drug-Induced Ocular Side Effects (www.eyedrugregistry.com) associating COX-2 inhibitors and visual adverse effects, prompting an examination of this first large series of spontaneous reports of possible adverse visual effects secondary to COX-2 inhibitors. The possible etiologies of the adverse ocular reactions are explored.
A total of 1006 reports were collected at the National Registry of Drug-Induced Ocular Side Effects (Casey Eye Institute, Portland, Ore). Spontaneous case reports from the National Registry, the Food and Drug Administration, and the World Health Organization were analyzed. The main information in the report from ophthalmologists includes the type of COX-2 inhibitor, age, sex, dosage, duration of therapy, concomitant therapies, and type of ocular adverse effect. Special attention was paid to reports with positive dechallenge and positive rechallenge, given that this information is the most compelling for a cause-and-effect relationship with COX-2 inhibitors causing a visual adverse effect.4 Spontaneous reports originated from the countries where the medications are marketed. Blurred vision and conjunctivitis were the majority of these types of reports and, therefore, are the focus of the results.
Celecoxib. There were 238 reported cases of blurred vision from celecoxib, with 67 positive dechallenge and 15 positive rechallenge reports. There were also 71 case reports of conjunctivitis due to celecoxib, with 12 positive dechallenge and 4 positive rechallenge reports. Average age was 58 years (range, 43-81 years) receiving standard doses (200 mg/d) with an average duration of therapy of 48 days. Three subjects also received diazepam in addition to celecoxib (1 conjunctivitis, 2 blurred vision).
Rofecoxib. A total of 258 reports of blurred vision from rofecoxib were collected, with 48 positive dechallenge and 21 positive rechallenge reports. There were 85 cases of conjunctivitis due to rofecoxib, with 18 positive dechallenge and 4 positive rechallenge reports. Average age was 62 years (range, 36-85 years) receiving standard doses (12.5-25 mg/d) with an average duration of therapy of 76 days. Two subjects with blurred vision were also taking levothyroxine and experienced visual hallucinations with positive dechallenge and positive rechallenge.
Valdecoxib. There were 14 case reports of blurred vision secondary to valdecoxib, with 3 positive dechallenge reports and 1 positive rechallenge report. There were also 14 case reports of conjunctivitis due to valdecoxib, with 1 positive dechallenge report and 1 positive rechallenge report. Average age was 60 years (range, 45-76 years) receiving standard doses (10 mg/d) with an average duration of therapy of 35 days.
Etodolac. Forty-eight case reports of blurred vision secondary to etodolac were received, with 11 positive dechallenge reports and 1 positive rechallenge report. Thirteen cases of conjunctivitis were reported, with 1 positive dechallenge report. Average age was 60 years (range, 22-91 years) receiving standard doses (200-400 mg/d) with an average duration of therapy of 19 days. From the rechallenge case, the patient was also taking aspirin with codeine.
Nimesulide. There were 11 cases of abnormal vision, with 4 positive dechallenge reports. Five reports of conjunctivitis were received, with 5 positive dechallenge reports. Average age was 52 years (range, 23-68 years) receiving standard doses (200-400 mg/d) with an average duration of therapy of 51 days.
Lumiracoxib. No ocular adverse effects have been reported related to this medication.
Conjunctivitis and blurred vision are the 2 main ocular adverse effects that appear to have a certain cause-and-effect relationship in some patients treated with COX-2 inhibitors, using World Health Organization criteria.4 This analysis is based on positive dechallenge and positive rechallenge data. Other ocular adverse effects were reported relatively infrequently and without complete follow-up and a clear relationship between COX-2 inhibitors and an adverse ocular reaction could not be deduced. In every instance, the ocular adverse effect resolved within 72 hours of discontinuation of the COX-2 inhibitor.
Spontaneous reporting databases collect information passively and have inherent limitations including incomplete data, duplicate reporting, lack of follow-up, and few data as to other diseases which could contribute to a clinical picture. After a drug is marketed, exposure to a medication goes from thousands in the clinical trial phase to millions in the marketing phase, and this is where postmarketing surveillance plays an important role. Incidence data cannot be garnered from passive databases such as the ones represented here; however, these databases can provide the earliest signals that a drug-induced adverse effect is occurring, especially if positive rechallenge reports are submitted. It appears that COX-2 inhibitors can cause blurred vision and conjunctivitis in some patients.
It is rare for clinicians to restart therapy if a drug-induced ocular adverse effect is suspected, as patients and physicians are reticent to undergo treatment with a drug they suspect is problematic. In spontaneous reporting databases, even a small number of positive rechallenge reports may be compelling evidence for a cause-and-effect relationship between a drug and an adverse reaction. World Health Organization classification of blurred vision and conjunctivitis due to therapy with some COX-2 inhibitors is certain given the very large number of positive rechallenge reports4- 5 and the similarity of the ocular symptoms on rechallenge to what they were before the medication was first discontinued. This is especially true for celecoxib and rofecoxib, which have an unusually large number of positive rechallenge reports.
Coulter et al2 propose a possible mechanism behind the blurred vision some patients experience when taking COX-2 inhibitors. Inhibition of synthesis of prostaglandins and other related compounds that control retinal blood flow could lead to visual changes. The vascular endothelium of retinal blood vessels produces compounds such as prostacyclin, thomboxane A2, and prostaglandin H2. Both COX-1 and COX-2 mediate synthesis of prostacyclin. Inhibition of either COX-1 or COX-2 may alter the cyclooxygenase pathway and in turn alter regulation of retinal blood flow with potential changes in vision.6 Other nonsteroidal anti-inflammatory medications have been reported to cause blurred vision, which is consistent with this theory.7- 8
In the case of selective COX-2 inhibitors, another mechanism may contribute to the blurred vision some patients experience. Four of the 6 COX-2 inhibitors are sulfonamides: celecoxib, rofecoxib, valdecoxib, and nimesulide. Sulfonamide medications are known to cause blurred vision through what is thought to be transient myopia. The mechanism is not fully understood but could include lenticular swelling, forward rotation of the lens-iris diaphragm, ciliary body swelling causing increased curvature of the lens surfaces, and spasm of accommodation.9- 12 The sulfonamide property of these COX-2 inhibitors could contribute to some cases of blurred vision. Curiously, the 2 non–sulfur-containing selective COX-2 inhibitors do not have the bulk of data to support a certain association with blurred vision, including a paucity of positive rechallenge reports.
Conjunctivitis also has a certain association with some COX-2 inhibitors. Again, there are a number of positive rechallenge reports for celecoxib and rofecoxib, giving strong evidence of a cause-and-effect relationship. This may not be unusual as many medications are secreted in tears. It is possible that these medications are secreted in tears as well, leading to a transient inflammation of the conjunctiva which resolves on discontinuation of the drug. Many examples of this exist—such as irritative conjunctivitis from oral diazepam or oral isotretinoin.13- 16
From the literature on this topic, there are mentions of visual field changes including unusual orange spots in vision, irregularly shaped visual field defects, and even a motor vehicle crash that occurred after a patient took celecoxib for 2 days.2- 3 It is possible that the blurred vision in the subjects listed here includes visual field changes and more severe visual disturbances, which could lead to loss of motor vehicle control, and which were categorized as blurred vision for lack of a better term.
Cyclooxygenase-2 inhibitors can cause blurred vision and conjunctivitis in some patients and clinicians should be aware of this association. Discontinuation of therapy leads to resolution without long-term sequela.
Correspondence: Dr Fraunfelder, Casey Eye Institute, 3375 SW Terwilliger Blvd, Portland, OR 97201 (email@example.com).
Financial Disclosure: None.
Funding/Support: This study was supported in part by an unrestricted grant from Research to Prevent Blindness, New York, NY, and by the National Registry of Drug-Induced Ocular Side Effects, available at www.eyedrugregistry.com, Casey Eye Institute, Oregon Health and Science University, Portland, Ore.
Country-Specific Mortality and Growth Failure in Infancy and Yound Children and
Association With Material Stature
Use interactive graphics and maps to view and sort country-specific infant and early
dhildhood mortality and growth failure data and their association with maternal
Thank you for submitting a comment on this article. It will be reviewed by JAMA Ophthalmology editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Purchase Online Access to this article for 24 hours
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 7
Customize your page view by dragging & repositioning the boxes below.
and access these and other features:
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.